Onyx Pharmaceuticals has a lot of clinical trials going on and development of drugs in the hopper.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today in
Blood, the medical journal of the American Society of Hematology, has published
their results from the 003-A1 Phase 2b trial, a single-arm, multicenter
clinical trial evaluating Kyprolis(TM) (carfilzomib) for Injection for the
treatment of patients with advanced multiple myeloma, who had received a median
of five prior anti-myeloma regimens.
